Letybo, an acetylcholine release inhibitor and a neuromuscular blocking agent, was approved in March 2024 based on data from three phase 3 trials.

Given the inverse relationship between spontaneous blinking and blink reflexes, a decrease in dopamine in the SNr would be expected to enhance reflexive blinking. This manifests clinically as the ...